Epigenomics/Roche: breast cancer pact decision delayed while colorectal cancer test shows promise
This article was originally published in Clinica
Executive Summary
Epigenomics said it has agreed that Roche Diagnostics' milestone and licensing decision for its tamoxifen response test for breast cancer will be postponed until the end of January 2006. Until then, Roche continues to have an option to obtain worldwide exclusive rights to the molecular test for an undisclosed milestone payment.